Truist Financial Issues Positive Forecast for AxoGen (NASDAQ:AXGN) Stock Price

AxoGen (NASDAQ:AXGN) had its price objective upped by research analysts at Truist Financial from $53.00 to $60.00 in a report released on Thursday, Benzinga reports. The firm currently has a “buy” rating on the medical equipment provider’s stock. Truist Financial‘s price objective points to a potential upside of 19.69% from the stock’s previous close.

Several other equities analysts have also recently issued reports on the company. Wells Fargo & Company boosted their target price on AxoGen from $48.00 to $56.00 and gave the company an “overweight” rating in a research note on Thursday. Jefferies Financial Group reissued a “buy” rating and set a $60.00 price objective on shares of AxoGen in a research report on Wednesday. Canaccord Genuity Group upped their price objective on shares of AxoGen from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AxoGen in a research report on Wednesday, August 26th. Finally, Lake Street Capital reaffirmed a “buy” rating on shares of AxoGen in a research report on Monday, October 5th. Twelve analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $56.91.

AxoGen Trading Up 1.8%

Shares of AXGN stock traded up $0.88 during mid-day trading on Thursday, reaching $50.13. The stock had a trading volume of 212,528 shares, compared to its average volume of 1,191,701. The firm has a market capitalization of $2.69 billion, a PE ratio of -73.09 and a beta of 1.17. The stock’s 50-day moving average price is $42.78 and its two-hundred day moving average price is $39.28. The company has a current ratio of 6.60, a quick ratio of 5.04 and a debt-to-equity ratio of 0.07. AxoGen has a 52-week low of $21.68 and a 52-week high of $52.91.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, October 28th. The medical equipment provider reported $0.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.08. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%. The company had revenue of $75.83 million for the quarter, compared to analysts’ expectations of $73.18 million. Equities analysts expect that AxoGen will post -0.44 earnings per share for the current fiscal year.

Insider Buying and Selling at AxoGen

In related news, EVP Marc Began sold 67,500 shares of AxoGen stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $47.34, for a total transaction of $3,195,450.00. Following the completion of the transaction, the executive vice president directly owned 50,135 shares of the company’s stock, valued at $2,373,390.90. This trade represents a 57.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Amy Wendell sold 13,353 shares of the company’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $48.42, for a total transaction of $646,552.26. Following the completion of the sale, the director owned 107,976 shares in the company, valued at approximately $5,228,197.92. This trade represents a 11.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 98,503 shares of company stock valued at $4,656,947. Insiders own 2.44% of the company’s stock.

Institutional Trading of AxoGen

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Nykredit A S bought a new position in AxoGen during the 2nd quarter valued at approximately $30,000. KBC Group NV bought a new stake in AxoGen in the first quarter worth $41,000. Sterling Capital Management LLC boosted its holdings in AxoGen by 858.9% in the third quarter. Sterling Capital Management LLC now owns 1,774 shares of the medical equipment provider’s stock worth $74,000 after acquiring an additional 1,589 shares in the last quarter. State of Alaska Department of Revenue grew its stake in shares of AxoGen by 16.9% in the third quarter. State of Alaska Department of Revenue now owns 2,833 shares of the medical equipment provider’s stock worth $118,000 after acquiring an additional 409 shares during the last quarter. Finally, Canada Pension Plan Investment Board bought a new position in shares of AxoGen during the second quarter valued at $203,000. Hedge funds and other institutional investors own 80.29% of the company’s stock.

Key Stories Impacting AxoGen

Here are the key news stories impacting AxoGen this week:

• Positive Sentiment: Q3 earnings and revenue exceeded expectations. AxoGen reported adjusted earnings of $0.21 per share, versus the $0.13–$0.14 consensus range, while revenue increased to $75.83 million from an expected $73.18 million. Earnings also improved from $0.12 per share a year earlier. AxoGen Beats Q3 Earnings and Revenue Estimates
• Positive Sentiment: Management raised 2026 revenue guidance. AxoGen now expects full-year revenue of at least $290 million, representing minimum growth of 29%. The higher outlook signals continued demand for its peripheral nerve repair products and was a key catalyst for investor enthusiasm. AxoGen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: HC Wainwright raised its price target to $56 from $53 and maintained a Buy rating. The revised target implies additional upside from the reported $49.25 reference price and reinforces the improving analyst view of AXGN’s growth prospects. HC Wainwright stock recommendations
• Positive Sentiment: Options activity reflected strong speculative interest. Investors purchased 9,886 call options, compared with average daily call volume of about 900, suggesting increased bullish positioning after the earnings release.
• Neutral Sentiment: Despite the earnings beat, AxoGen continues to report a negative net margin and negative return on equity. Its elevated valuation following the rally could also limit further gains unless revenue growth and profitability continue to improve. Does AxoGen Have More Upside?

AxoGen Company Profile

AxoGen, Inc (NASDAQ: AXGN) is a medical technology company focused on developing and commercializing products for the repair and regeneration of peripheral nerves. Its technologies are designed to help restore sensory and motor function following traumatic injuries, surgical procedures, and other conditions affecting peripheral nerves.

The company’s product portfolio includes Avance Nerve Graft, a processed human nerve allograft used to bridge gaps in damaged nerves without requiring tissue to be taken from another part of the patient’s body.